Clinical Trial Update: ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML [Phase 1]

View source ↗

Summary

Clinical trial update for ACHIEVE2 reports safety and preliminary efficacy data for intravenous TCB008 in patients with relapse or refractory acute myeloid leuk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• TCB008 (TCB008)

Snippet

Sponsor: TC Biopharm | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: NOT_YET_RECRUITING